Background. Schistosomiasis traditionally has been diagnosed by detecting eggs in stool or urine. However, the sensitivity of these examinations is limited, especially in travelers with a low worm burden. Serologic tests have a greater sensitivity, but their results remain positive regardless of treatment and thus cannot be used for follow-up of patients. We hypothesized that detection of worm microRNAs (miRNAs) in serum can overcome the drawbacks of the existing diagnostic methods.
Schistosomiasis (also known as bilharziasis) is a parasitic infection caused by several species of blood flukes from the genus Schistosoma. The 3 main species causing human disease are Schistosoma mansoni (in Africa), Schistosoma haematobium (in Africa), and Schistosoma japonicum/mekongi (in Southeast Asia). Schistosomiasis is a common parasitic infection that affects >200 million people in 75 countries, mostly in the developing world [1] . The greatest burden of the disease is in Africa, where it is hyperendemic in many regions. Schistosome infections are also diagnosed in areas of nonendemicity, in immigrants and travelers returning from schistosomiasis-endemic countries. Infection in returning travelers, including Israelis, has received increasing attention [2] .
The current diagnostic methods rely on examination of stool and urine specimens, to detect parasite eggs, and on serologic testing [3] . However, especially in travelers, the sensitivity of stool and urine examinations is limited, owing to the low worm burden and the sporadic passage of eggs [4] . In addition, travelers might develop acute illness shortly after exposure (ie, acute schistosomiasis), which occurs several weeks before oviposition by the adult worms. Thus, stool and urine examinations performed at this time are unrevealing: in one study, ova were detected by microscopy in only 25% of Israeli travelers who had clinical findings indicative of schistosomiasis [2] . Serologic tests have a much greater sensitivity, depending on the kit [5] , and usually begin to yield positive results 4-6 weeks after exposure, but they remain positive even after successful treatment. Therefore, they are not useful for the assessment of cure or for the detection of a second exposure.
Our general aim in this work was to search for a molecular method of detection that could identify parasites early during infection and their clearance after successful treatment. Polymerase chain reaction (PCR) for detection of schistosomal DNA has equivocal results; Pontes et al compared the sensitivity of schistosomal DNA detection in stool by PCR to that of isolation of eggs by the Kato-Katz concentration method and found the PCR method much more sensitive. They also demonstrated that PCR can detect schistosome DNA in patients' sera but did not evaluate its sensitivity or specificity [6] . Wichmann et al showed a sensitivity of 92% in detecting schistosomal DNA by PCR in sera from infected patients, but neither the specificity of the test nor its value in follow-up of patients after treatment was evaluated [7] .
Our specific aim, therefore, was to detect parasitic infection by identifying parasite microRNAs (miRNAs) in sera from infected humans. miRNAs are widely found in unicellular and multicellular organisms, including S. mansoni and S. japonicum [8] [9] [10] [11] . miRNAs have the advantage of being genus specific [12] and relatively stable [13] . Our first attempt was to detect schistosomal infection in exposed travelers by quantitative PCR (qPCR) for schistosomal miRNAs extracted from sera. However, the sensitivity of qPCR analysis was low.
Since miRNAs are known to be part of the cargo carried by extracellular vesicles (EVs) and since exosome-like EVs are secreted by S. mansoni [14, 15] , we attempted to detect parasitic RNA species within EV extracted from human sera.
Exosomes are 50-100-nm vesicles originating from the endosomal membrane and released from the cell into the extracellular space [16] , possibly serving as an intercellular mode of communication [17, 18] , including communication between parasites [19] [20] [21] . Exosomes contain a variety of cargo molecules, including proteins, lipids, DNAs, messenger RNAs, and miRNAs [17] . Our assumption was that schistosomal miRNAs are not freely circulating in patients' sera but, rather, are mainly enclosed in EVs and, therefore, that isolation of EVs from sera of infected patients may increase our ability to detect even small amounts of schistosomal miRNAs and, thus, increase their value as a markers for Schistosoma infection.
MATERIALS AND METHODS

Patients' Samples
RNA was extracted from sera of Schistosoma-infected travelers before and after treatment. Diagnosis of schistosome infection was based on a history of exposure to freshwater in regions of endemicity and either positive results of schistosome-specific serologic testing and/or the presence of schistosome eggs in stool or urine specimen. Schistosome-specific serologic testing was performed at the parasitology laboratory of the Israeli Ministry of Health, Jerusalem, Israel. Serologic analysis was performed with the Microwell enzyme-linked immunosorbent assay kit (Schisto-96; SciMedX), and results were confirmed by detection of Schistosoma species via Western blot (LDBio Diagnostics, Lyon, France).
Species-specific diagnosis was based on the detection of ova in stool or urine specimens or when exposure occurred in a region where a single species was the predominant one. All patients were treated with praziquantel at dose of 60 mg/kg. Sera from healthy donors who had never been in schistosomiasis-endemic areas were used as controls.
Human blood specimens were collected after written informed consent was obtained. The study was approved by the Chaim Sheba Medical Center Ethics/Institutional Review Board (Helsinki) Committee (Helsinki no. 2729-15-SMC).
miRNA Extraction From Human Sera Samples
Blood samples, which were collected in BD Vacutainer K2E tubes containing ethylenediaminetetraacetic acid (catalog no. 367 864; BD, Plymouth, United Kingdom), were centrifuged at 1500×g for 7 minutes to extract serum, and sera were stored at −80°C until analysis. miRNA was isolated directly from 500 μL of patient and control sera, using the miRVana PARIS protein and RNA isolation kit (catalog no. AM1556; Ambion) according to the manufacturer's protocol.
EV Isolation From Human Sera Samples
We extracted EVs from 200 μL of patient and control sera, using ultracentrifugation as described elsewhere [22, 23] . Serum was diluted in 4 mL of phosphate-buffered saline (PBS) and centrifuged at 11 000×g for 10 minutes at 4°C. Afterward, the samples were ultracentrifuged at 100 000×g at 4°C. The supernatant was discarded, and the pellet was suspended in 200 μL of PBS for RNA extraction. miRNAs were extracted from EVs by using the Plasma/Serum Circulating Purification mini-kit (catalog no. 51 000; Norgen Biotek) according to manufacturer's protocol.
Sucrose Gradient Preparation Using the OptiPrep Density Gradient
Technique to Detect Exosome, miRNA, and CD63 EV Protein
The discontinuous iodixanol gradient was prepared as described elsewhere, using OptiPrep density gradient technique (Cosmo Bio USA) [24] . A total of 500 μL of Schistosoma-infected human sera was overlaid on the gradient, and centrifugation was performed at 100 000×g for 22 h at 4°C. Thirteen fractions, each containing 1 mL, were collected (from top to bottom). Each fraction was diluted with 6 mL PBS and centrifuged at 100 000×g overnight at 4 °C, and the pellet was resuspended in 100 μL of PBS.
In the next step, RNA was extracted from 50 μL of each fraction (as described above) and subjected to TaqMan quantitative reverse transcription PCR (qRT-PCR) to detect miRNAs, as described by the manufacturer (Applied Biosystems, Foster City, CA), using primers specific to either schistosomal miRNA bantam (assay 006598_mat; Applied Biosystems, Foster City, CA) or schistosomal miR-10-5p (assay 244531_mat; Applied Biosystems).
The remaining 50 μL of each fraction was subjected to Western blot analysis, using anti-human CD63 antibodies (catalog no. A1502-50; BioVision).
1-Step Real-Time RT-PCR
The ABI Step One Plus Real-Time PCR System (Applied Biosystems, Foster City, CA) was used for amplification and detection of miRNAs by Eva Green technology, as previously described [25] . Briefly, 1 μL of 5X ProtoScript II Reverse Transcriptase Buffer (catalog no. M0368L; BioLabs), 0.5 μL of DTT (10 mM 
Primers for Schistosome miRNA Detection
The primers for Schistosoma bantam were as follows: RP1-bantam, 5'-GGACGGTAGCAAGCAAAGAGTGTGACCAGCTTTA ATC-3'; RP2-bantam, 5'-GGATTCTGGAAGATGATGATG ACTGAGATCGC-3'; P1, 5'-GGACGGTAGCAAGCAAAGA GTGTG-3'; and P2, 5'-GGATTCTGGAAGATGATGATG AC-3' . Primers for Schistosoma miR-3488 were as follows: RP1-3488, 5'-GGACGGTAGCAAGCAAAGAGAGAGACCA ACTAAG-3'; RP2-3488, 5'-GGGATTCTGGAAGATGAT GATG ACGCTCCGGTAG-3'; P1-3488, 5'-GGACGGTAGCAAGCAA AGAGAGAG-3'; and P2-3488, 5'-GGGAT TCTGGAAGATG AT GATGAC-3' . Primers for Schistosoma miR-2c-3p were as follows: RP1-2c-3p, 5'-GGACGGTAGCAAGCAAAGAGAG AGGCCCTTAAGCACG-3'; RP2-2c-3p, 5'-GGGATTCTG GAAGATGATGATGACTATCACAGC-3'; P1-2c-3p, 5'-GG ACGGTAGCAAGCAAAGAGAGAG-3'; and P2-2c-3p, 5'-GG GATTCTGGAAGATGATGATGAC-3' . Primers for Schistosoma miR-2a-5p were as follows: RP1-miR-2a-5p, 5'-GGACGG TAGCAAGCAAAGAGTGTGTGCCTTCAG-3'; RP2-miR2a-5p, 5'-GGATTCAGGAAGATGATGATGAGCAGTCAAT ATTGG-3'; and P1-miR-2a-5p, 5'-GGACGGTAGCAAGCA AAGAGTGTG-3'; and P2-miR-2a-5p, 5'-GGATTCAGGAAGA TGATGATGAG-3' .
Statistical Analysis
Statistical significance was evaluated using Student t test. A P value of <.05 was considered statistically significant. The 95% confidence interval (CI) according to Wilson was determined using VassarStats' Clinical Calculator 1 (available at: http:// faculty.vassar.edu/lowry/clin1.html). The unpaired t test and area under the receiver operating characteristic (ROC) curve analysis were performed using GraphPad Prism, version 5.00, for Windows (GraphPad Software, San Diego, CA; available at: http://www.graphpad.com).
Briefly, after entering data from infected individuals and healthy controls, a series of cutoffs was calculated, using all delta threshold cycle (Ct) values from each group. The graph plotted the sensitivity as a function of the false-positive rate (calculated as 100 − specificity) for the different cutoffs. The optimal cutoff was determined as the cutoff with the highest likelihood ratio (calculated as the sensitivity/[100 − specificity]).
RESULTS
Twenty-six patients (14 males and 13 females) were included in the study. Their mean age (±SD) was 27 ± 8.1 years. All were travelers returning from either sub-Saharan Africa (n = 24) or Laos (n = 2). All had a history of exposure to fresh water in the schistosomiasis-endemic regions, and all (except 1) presented clinical symptoms compatible with schistosomiasis or high-level eosinophilia [ Table 1 ]. Only patients who initially presented within <5 years from the last exposure were included. The time from patients' exposure to the time when blood samples were collected ranged from 1 to 8 months. Diagnosis was based on serologic findings in all cases, and 4 patients were also positive for ova in stool or urine specimens (Table 1) . On the basis of the area of exposure or the morphology of ova, 17 patients had S. mansoni infection, 4 had S. haematobium infection, and 2 had S. mekongi infection; 3 patients were infected in Africa, but the species in each case was unknown. Sera from 17 healthy individuals who had not traveled to areas of endemicity served as controls.
Detection of Schistosomal miRNAs in Sera of Infected Patients
We first attempted to detect schistosomal miRNAs in serum by the conventional method of TaqMan miRNA assays. The miRNAs that were initially chosen were bantam and miR-125b. However, amplification was detected at high Ct values (48 for bantam and 51 for miR-125b). In addition, some healthy control samples occasionally gave positive results (data not shown). Therefore, we adopted a 1-step real-time RT-PCR analysis, claimed to be sensitive enough to detect 0.1-10 fmol of specific miRNAs [25] . Using this method, we evaluated 2 schistosomal miRNAs: bantam and miR-3488. Bantam analysis was performed for 18 patients and 7 healthy individuals in 3 experiments. As can be seen in Figure 1 , we found a statistically significant difference between 18 infected patients and 7 healthy individuals (P = .021). Using this definition, 6 of 18 infected patients' samples were considered negative, suggesting a sensitivity of 66%.
In 1 of 7 healthy samples, the ΔCt value was above the cutoff, suggesting a specificity of 85% (Table 2) . Unlike bantam, when miR-3488 was measured in 14 infected and 5 healthy control samples, the miR-3488 level did not differ between the infected and healthy samples (P = .5540; Figure 1 ), implying nonspecific (false-positive) amplification.
Considering these results, we decided to evaluate the presence of schistosomal miRNAs in the EV fraction harvested from patient sera, a fraction that we hypothesized might be enriched by these RNA molecules. The EV were separated from the sera as described in Methods. Under these conditions, most EV will precipitate by ultracentrifugation at 100 000 × g [18] . To verify that the miRNAs we identified were associated with the EV fraction, we performed an OptiPrep density sucrose gradient experiment (see Methods). We demonstrated that there was almost a complete overlap between the fractions containing the schistosomal miRNA and those containing the CD63 protein, which is a well-known marker for EV [26] (Figure S1 ).
After isolating the EV, RNA was extracted and subjected to 1-step qRT-PCR analysis. Four different miRNAs-bantam, miR-3488, miR-2c-3p, and miR-2a-5p-were evaluated. As shown in Figure 2 , a significant difference in ΔCt was found between infected patients and healthy individuals. Detection of schistosomal microRNAs (miRNAs; bantam and miR-3488) in human sera. RNA was extracted from the sera and subjected to 1-step reverse transcription polymerase chain reaction analysis (see Methods) with specific primers to bantam (blue dots) and miR-3488 (red dots). Each dot represents patients' or healthy individual's samples. For each miRNA, the mean cycle threshold (Ct) for all healthy individuals was calculated, and the ∆Ct of each sample was calculated as the subtraction from this mean. The P value was calculated by an unpaired t test, and mean values ± standard errors of the mean are depicted. For bantam, P = .0213, and for miR-3488, P = .5540. We used a ROC test to validate the accuracy of our test. The area under the curve (AUC) determines the inherent ability of the test to discriminate between the diseased and healthy populations. Accuracy is measured by the AUC; an area of 1 represents a perfect test, and an AUC of 0.5 represents a worthless test [27] . As shown in Figure 3 , the accuracy of analyzing the expression of schistosomal miRNAs extracted directly from the sera of infected patients was not high: the bantam AUC was 0.786 ( Figure 3B ), and the miR-3488 AUC was not statistically significant (P = .3546; Figure 3B ). However, the accuracy of analyzing the expression of schistosomal miRNAs extracted from EV was very high, with an AUC of >0.91 and a P value of < .0001 for 3 different miRNAs (bantam, miR-2c-3p, and miR-3488; Figure 3A) . The additional advantage of this assay is that an optimal cutoff can be determined. For bantam, based on the cutoff defined by the AUC graph, a sensitivity of 85.71% and specificity of 94.12% were found, and miR-2c-3p had a sensitivity of 85% and a specificity of 93.75% (Table 2) .
This cutoff was used to calculate the combined specificity and sensitivity for the 2 miRNAs that were found to have the highest and most significant ΔCt, bantam and miR-2c-3p ( Figure 2B ). The combined sensitivity was increased to 91%, and the combined specificity was decreased to 82% (Table 2) .
Our assumption that effective treatment will eliminate the schistosomal miRNAs from the infected patients' sera was also tested. To address this issue, we collected sera from 7 patients who were positive before treatment and underwent follow-up after treatment. The follow-up duration ranged from 11 weeks to 10 years. Both bantam and miR-2c-3p were tested. As can be seen in Figure 3 , there was a significant decline in the ∆Ct after treatment in both miRNAs. It seems that there was a slow decline in the levels of miRNAs; 11 weeks after treatment, the results were still low positive, while approximately 32 weeks after treatment, there was a higher chance to obtain negative results. In total, 5 of 7 patients were considered healthy, owing to negative posttreatment results, while 2 others with relatively short follow-up had a significant decline in miRNA levels but did not yet have negative results (Figure 4 ).
DISCUSSION
Diagnosis of Schistosoma infections is currently challenging, and a reliable tool for follow-up of therapeutic efficiency is lacking. Our novel approach to diagnose the infection by detecting parasitic miRNAs within EV fractions seems to be highly promising. Our target population of infected travelers, known to have a low-burden of infection, is even more challenging and therefore emphasizes the yield of this method of extracting the miRNAs from the EV fraction, rather than directly from the serum. Even with a more sensitive method, 1-step real time RT-PCR analysis of serum, which is able to detect levels of specific miRNAs as low as 0.1 fmol to 10 fmol [25] , results were inferior to those of the microvesicle concentration method. Results of direct serum testing showed that only the schistosomal miRNA bantam could distinguish between infected and healthy individuals, although it had low sensitivity and specificity.
There are already several reports showing that miRNAs are cargo of EVs [17] . Thus, our hypothesis that the parasitic miRNAs might be part of the cargo of EVs appears to be true ( Figure  S1 ), and we were able to enrich the concentration of the schistosomal miRNAs by performing PCR on the extracts of the EV fraction isolated from serum. In our study, we used 4 different miRNAs (bantam, miR-2c-3p, miR-3488, and miR-2a-5p), and in all 4 there was a statistically significant difference in the ∆Ct of infected patients as compared to healthy individuals (Figure 2) . When combining the 2 miRNAs with the highest ΔCt (bantam and miR-2c-3p), the sensitivity was 80%-86%, and the specificity was 84%-94%, which is similar to the serological test results [5] . Moreover, the AUC analysis found this assay to be highly accurate (Figure 3) .
Currently, most valid methods cannot serve as follow-up tests for infected patients and predict the success of anti-Schistosoma treatment. Our results clearly show that in all patients in whom parasite miRNAs were detected before treatment, posttreatment evaluation showed a decrease in miRNA levels, even as early as 11 weeks after treatment. The complete disappearance of the miRNAs was variable; in some patients, it happened within 32 weeks after treatment, while in others, the ∆Ct dropped significantly a As defined by the area under the curve.
b Samples with a delta threshold cycle above the cutoff for any of the miRNAs were considered positive.
(but was still considered positive) 32 weeks after treatment ( Figure 4) . Overall, we are confident that 5 of 7 patients were cured. It is important to note that the advantage of following up a populations of returning travelers was that they reside in a country where schistosomiasis is not endemic (among our cases, all reside in Israel), and none of them traveled back to countries of endemicity, allowing for accurate follow-up. Two recent studies aimed to detect schistosomal miRNAs directly from sera. These investigations were done in animal models (mice and rabbits) in which the animals were infected with high inocula of cercariae [28, 29] . Only 1 study attempted to identify schistosomal miRNAs in infected humans. In this study, the patients were from areas where schistosomiasis is endemic (Uganda and Zimbabwe) and levels of infection are moderate or high [30] . Among the patients in this study with eggs detected in stool samples (107-1117 eggs per gram of stool), the researchers were able to detect 3 schistosomal miRNAs (bantam, miR-277, and mirR-3479-3p) extracted directly The ∆Ct of each sample was calculated as described in Figure 1 . Mean values ± standard errors of the mean are depicted. P value was calculated by 478 unpaired t test ***P < .0001, *P = .0413. Numbers of samples evaluated were as follows: for bantam, 17 from healthy individuals and 21 from infected individuals; for miR-2c-3p, 16 and 20, respectively; for miR-3488, 15 and 20, respectively; and for miR-2a-5p, 4 and 12, respectively. from their sera, with a specificity of 80% and sensitivity of 90% [30] . However, in individuals without eggs in their stool, who may still have a low burden infection, tests for detection of serum miRNA were negative. Furthermore, there was no attempt to follow them after treatment.
An additional schistosomal, nonmolecular diagnostic tool that targets circulating anodic antigen (CAA) and circulating cationic antigen (CCA). The assay detects circulating antigen in serum and urine of patients with active infections at very low levels, including single-worm infections [31] . The assay was developed into an up-converting phosphor lateral-flow assay, which allows rapid field screening and was found to be highly sensitive for both S. japonicum and S. mansoni, especially in urine samples [32] . During screening in China, it was found to have the highest sensitivity when compared to other assays. The sensitivity for detection of CAA in urine was 93% and that for detection in serum was 73%, whereas the triplicate Kato-Katz thick smear assay had a very low sensitivity of only 13% [33] . The published data for the CAA assay came from patients in schistosomiasis-endemic countries with high burdens of infection. [34] . One study in travelers also showed that the CAA/ CCA assay is a sensitive tool, detecting 85% of cases, and could be used for treatment follow-up, as most of the patients become negative after 7 months after treatment [35] .
The miRNA-based assay has a major advantage. Since the sequences of the mature miRNAs are identical in the 3 major schistosomal species of S. mansoni, S. haematobium, and S. japonicum/mekongi [36] (unpublished data, I. Ben-Dov, D. Avni, and E. Schwartz), the sensitivity of the test might be similar for all species. Among our patients, the majority had S. mansoni infection, but 4 were infected with S. haematobium, and 2 were infected with S. mekongi, and there was no difference in our ability to detect the worm miRNAs in these groups. This is not the case with the serological test, for which there is a major decrease in the sensitivity for S. haematobium and no information regarding its sensitivity for S. mekongi [5] .
An additional advantage is the capability of this method to assess infected patients and predict the success of anti-Schistosoma treatment. This capability is paramount in schistosomiasis, which has historically responded to praziquantel, although after several decades of massive use reports of resistance to this agent are now emerging [37] [38] [39] . In addition, even after eradication efforts, patients with a low burden of infection, which cannot be detected by the usual methods, can remain a reservoir for disseminating the disease. Thus, a diagnostic method that can detect and follow individuals with even low burdens of infection is crucial.
The limitation of our study is the relatively low number of patients. However, our results are encouraging, and efforts should be made to increase the number of tested patients and expand the repertoire of detectable Schistosoma miRNAs, with the hope of increasing sensitivity and specificity.
Overall, our results suggest that schistosomal miRNAs extracted from isolated serum EVs may serve both as diagnostic 02939; for miR-3488, P = .3546. ROC curves were performed using GraphPad Prism, version 5.00 for Windows. The diagonal black line reflects the performance of a diagnostic test that is no better than chance. True-positive rates were calculated as the sensitivity, and false-positive rates were calculated as 100 − specificity.
tools for infection and for following up the efficacy of treatment, even in patients with a low burden of infections, such as infected travelers. This novel approach can be applied to other parasitic infections, since each species should have its own unique miRNA sequences.
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Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. Figure 4 . Schistosomal microRNA (miRNA) expression in extracellular vesicle (EV) fractions of human sera before and after treatment. The graphs represent the change in ΔCt, calculated as described in Figure 1 , for each patient after treatment. Each patient is presented by 2 dots that are connected by blue lines. The light blue area under the red fragmented line marks the ΔCt that we considered healthy.
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